Objective: To explore the association between APOE*4 and pathologically confirmed cases of the Lewy body (LB) variant of Alzheimer disease (AD). Methods: With use of ␣-synuclein (AS) immunohistochemistry, LBs were detected in 74 of 131 (56.5%) of the AD ϩ LB cases; the remaining 57 cases (43.5%) did not have LBs. Results: There were no differences in gender or age between Caucasian subjects with AD ϩ LB or AD alone or control subjects. The APOE*4 allele frequency was highest in the AD ϩ LB group (47.3%; 95% CI ϭ 37.8 to 57.0%), intermediate in the AD-alone group (35.1%; 95% CI ϭ 25.3 to 46.3%), and lowest in the control group (14.2%; 95% CI ϭ 10.5 to 18.9%). With use of logistic regression analysis, the odds of having AD ϩ LB vs AD alone were 2.1-fold (95% CI ϭ 1.0 to 4.5, p ϭ 0.055) greater in persons with an APOE*4 allele than in those without an APOE*4 allele. Conclusion: The APOE*4 allele is associated with the presence of concomitant Lewy bodies in Alzheimer disease.
There is a strong association between APOE*4 and Alzheimer disease (AD), but the role of APOE in the susceptibility to develop the Lewy body (LB) variant of AD (AD ϩ LB) is uncertain. Studies that investigate APOE*4 as a risk factor for AD ϩ LB have had conflicting results. Some studies suggest that APOE*4 allele frequency is similar in AD ϩ LB and in AD alone. 1, 2 Others report that the APOE*4 allele frequency in AD ϩ LB either falls between that of AD-alone cases and normal control subjects 3, 4 or is higher than that of AD-alone cases. 5 Conversely, another recent study reported an increased frequency of the APOE*3/*4 genotype only in males with AD ϩ LB. 6 Interestingly, the APOE*4 allele is associated with increased neocortical LBs in patients with Parkinson disease (PD) with dementia. 7, 8 Unfortunately, because of the varying clinical and neuropathologic classification of AD ϩ LB and PD with dementia, comparisons between studies are difficult. Furthermore, none of the published studies investigating the association between APOE and AD ϩ LB has used the most sensitive methods for LB detection (i.e., ␣-synuclein [AS] immunostaining and amygdala sampling). With use of these more sensitive methods of LB detection, the current study investigates the relationship between the APOE*4 allele and LBs in neuropathologic AD.
Methods. Study population. All assessments were conducted after obtaining written informed consent from subjects according to procedures approved by the University of Pittsburgh Institutional Review Board. Only subjects with APOE genotype available from a blood sample or postmortem tissue were considered for inclusion in the study.
The study consists of 133 patients who were clinically diagnosed as having "probable AD" using the National Institute of Neurological and Communication Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria 9 at the Pittsburgh Alzheimer's Disease Research Center from 1995 to 2001. Brains were examined as previously described. 10 All 133 patients met the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropathologic criteria for the diagnosis of "definite AD." 11 One hundred thirty-one cases were classified as Braak stage III or above, thus fulfilling the National Institute on Aging and Reagan Institute (NIA-RI) criteria for "intermediate or high" likelihood that dementia is due to AD. Ninety-six cases were classified as Braak stage V or VI, thus fulfilling the NIA-RI criteria for "high" likelihood that dementia is due to AD.
The control group included 197 participants in the Monogahela Valley Independent Elders Survey (MoVIES). MoVIES was a prospective community study of cognitive impairment and dementia in the semirural mid-Monongahela Valley region of southwestern Pennsylvania. Sampling, recruitment, and clinical dementia assessment for MoVIES have been described previously. 12 The 197 control subjects provided blood samples for APOE genotyping between 1994 and 1997 and were not demented on the date that blood was drawn.
We excluded non-Caucasian subjects from both the case and the control groups because the association between APOE genotyping and AD differs across ethnic groups. 13 We did not have sufficient non-Caucasian subjects to analyze results from these ethnic groups separately.
Clinical assessments. Each subject underwent an extensive neuropsychiatric evaluation. This assessment included a medical history and physical examination, a neurologic history and examination, and behavioral and neuropsychological evaluations. Subjects with objective evidence of progressive alterations in functional status secondary to cognitive deficits were diagnosed with dementia. The diagnosis of dementia also required that, in the absence of reversible causes of cognitive impairment, neuropsychological testing reveal impairments in two or more cognitive domains. Once a subject was diagnosed as having dementia, we applied the NINCDS-ADRDA criteria for AD and excluded subjects with other potential causes of dementia. At least two experienced clinicians agreed on a consensus diagnosis for each subject.
Neuropathologic assessments. The pathologic diagnoses for this study were based on an examination of the following brain areas: frontal cortex, anterior cingulate gyrus, insular cortex, amygdala, hippocampus, entorhinal and trans-entorhinal cortices, parietal cortex, superior and middle temporal cortices, thalamus, caudate nucleus, putamen, globus pallidus, substantia nigra, and locus ceruleus. Each case was examined for the presence of senile plaques and neurofibrillary tangles using modified Bielschowsky stain. The neuropathologic diagnosis of AD was based on CERAD and NIA-RI neuropathologic criteria. 11, 14 AS immunostaining with protease pretreatment. The paraffin blocks were cut at 6 m. Our study identified LBs using monoclonal antibodies against AS. 10 The deparaffinized sections of the appropriate regions were digested for 1 minute with a 100 mg of type XXIV protease (Sigma-Tau Pharmaceutical, Gaithersburg, MD) in 300 mL of distilled water at 37°C; next, the primary antibody was diluted in a common antibody dilutor (1:1,200 for LB509; Zymed, San Francisco, CA). The staining was visualized using a commercially available kit (LSAB-2 kit; Dako, Carpinteria, CA) containing diaminobenzidine. Then the tissue was counterstained with Mayer hematoxylin. All round, homogeneously AS-positive structures were considered LBs, including intracytoplasmatic, intraneuritic, and extracellular LBs.
AS immunostains were performed on all paraffin blocks. As previously reported, 10 all AD ϩ LB cases had LBs in the amygdala, but in some cases, there were no LBs detected in other areas of the brain or brainstem. 10 We evaluated the extent of LB formation using a semiquantitative LB scoring system (LB score) based on the International Consensus Criteria for the diagnosis of dementia with LBs (DLB). 15 Our assessments included a determination of the presence or absence of LBs and an assessment of the severity (semiquantitative) of LB pathology in paraffin blocks from the following regions: frontal, parietal, temporal, anterior cingulate gyrus, and trans-entorhinal cortices. 16 We then counted LBs in a designated area of the AS-stained section. 15 Each area was given a score of 0, 1, or 2. A score of 0 corresponded to an absence of LBs, a score of 1 to the presence of one to five LBs, and a score of 2 to more than five LBs in the area of evaluation as specified by the International Consensus Criteria for the diagnosis of DLB. 15 Scores from these five regions were then summed. Cases without LBs were assigned a score of "negative," whereas a total LB score of 0 indicated the presence of minimal neocortical LBs (with LBs restricted to the amygdala), and a total LB score of "10" indicated the presence of widespread neocortical LBs. As LB pathology in the amygdala was not specifically addressed in the International Consensus Criteria, these cases were grouped with the brainstem-predominant cases. Cases with a total LB score of 0 were classified as brainstem/amygdala, cases with a total LB score of 1 to 6 were classified as limbic, and cases with a total LB score of 7 to 10 were classified as neocortical.
APOE genotyping. DNA was isolated with the QIAmp kit from Qiagen (Chatsworth, CA). Genotyping was performed using an established PCR protocol that was described previously. 17 Statistical analysis. Neuropathologic AD cases were divided into two categories: AD alone and AD ϩ LB. The latter cases were defined by the presence of any number of AS-immunoreactive LBs in any neocortical, amygdala, or brainstem section. Subsequent analyses examined the relationship of the APOE genotypes to our semiquantitative measure of cortical LB density. Continuous variables were compared using t tests for two-group comparisons and analysis of variance for three-group comparisons. Categorical variables were compared using 2 statistics. APOE allele frequencies were calculated by the allele-counting method. The relationship between the APOE*4 allele frequency and the presence of concomitant LB pathology was explored using logistic regression analyses. Effect modification was explored by stratifying by gender. This decision was influenced by the results of previous studies, which observed a stronger APOE*4-AD association in women than men. 13 Separate analyses were conducted for all cases with Braak stage IIIC or higher (intermediate or high pathologic criteria for AD) and cases with only Braak stage VC or higher (high pathologic criteria for AD).
Results. Classification of AD and AD ϩ LB. After applying intermediate or high pathologic criteria for AD criteria (Braak stage IIIC or higher), the study sample consisted of 131 Caucasian cases of clinically diagnosed and neuropathologically confirmed AD and 197 nondemented Caucasian control subjects. All 131 AD cases satisfied NIA-RI neuropathologic criteria for having either an intermediate or a high likelihood that dementia was due to AD. AS immunohistochemistry detected LBs in 74 of 131 (56.5%) of the cases (AD ϩ LB), whereas 57 cases (43.5%) did not have LBs (AD alone).
Clinical and demographic characteristics. Table 1 shows both the demographic characteristics of the control subjects and patients with AD (AD alone and AD ϩ LB) and the clinical characteristics of the AD cases. The proportion of men and women and the age at study enrollment were similar in all three groups. Furthermore, comparison between cases with AD (without and without LBs) showed similar education level, age at onset, age at death, and duration of illness.
These results did not change when the analyses were repeated on cases with only high pathologic criteria for AD. Therefore, subsequent analyses include all cases with intermediate or high pathologic criteria for AD.
APOE allele frequencies.
The APOE allele frequencies (see table 2) within the control group, group with AD alone, and group with AD ϩ LB were each in Hardy-Weinberg equilibrium (p Ͼ 0.9 all groups). The distributions of APOE allele frequency demonstrated that APOE*4 allele frequencies were highest in the AD ϩ LB group (47.3%; 95% CI ϭ 37.8 to 57.0%), intermediate in the ADalone group (35.1%; 95% CI ϭ 25.3 to 46.3%), and lowest in the control group (14.2%; 95% CI ϭ 10.5 to 18.9%).
The APOE*4 allele frequency in the AD ϩ LB cases was higher than that found in AD-alone cases ( 2 ϭ 3.94, df ϭ 1, p ϭ 0.05) as well as that found in control subjects ( 2 ϭ 66, df ϭ 1, p Ͻ 0.001).
Logistic regression analyses. Logistic regression analysis showed that the odds of having AD ϩ LB vs being a control were 9.1-fold (95% CI ϭ 4.9 to 17.0, p Ͻ 0.0001) greater in persons with an APOE*4 allele than in persons without an APOE*4 allele. The odds of having AD ϩ LB vs AD alone were 2.1-fold (95% CI ϭ 1.0 to 4.5, p ϭ 0.055) greater in persons with an APOE*4 allele than in those without an APOE*4 allele.
In exploratory analyses, the odds of having AD ϩ LB vs AD alone were 2.8-fold (95% CI ϭ 0.9 to 9.3, p ϭ 0.08) greater in men with an APOE*4 allele than in men without an APOE*4 allele. In women, the odds were 2.0-fold (95% CI ϭ 0.7 to 5.5, p ϭ 0.2) greater in persons with an APOE*4 allele than in those without an APOE*4 allele. Although neither odds ratio was significant, there was a trend toward significance in the men.
APOE by age at onset. Within both AD groups (with and without LBs), individuals with one or two APOE*4 alleles had a younger age at onset than those with no APOE*4 alleles, but these differences were not significant.
APOE allele frequencies by total LB score. The extent of LB formation in AD ϩ LB cases ranged from those with numerous neocortical and nigral LBs to cases with LBs only in the amygdala. Of the AD ϩ LB cases, 31 of 74 (41.9%) received total LB scores of 7 to 10, whereas the remaining cases (43/74 ϭ 58.1%) received total LB scores that were Ͻ7 (figure). With use of our modified consensus neuropathologic classifications (where brainstem/amygdala predominant was defined as total LB score of 0, limbic was defined as a total LB score of 1 to 6, and neocortical was defined as a total LB score of 7 to 10), AD ϩ LB cases were further divided according to the degree of neocortical AS-immunoreactive LB accumulation. There was no significant association between APOE*4 allele frequency and extent of neocortical LB involvement.
Braak stage by APOE genotype. Comparison of Braak stage by APOE genotype demonstrated that the APOE*4 allele frequencies were lower in AD-alone cases with Braak stages III or IV (25%) than in AD-alone cases with Braak stages V and VI (38%). However, there was no clear association between Braak stages and APOE allele frequencies in cases with AD ϩ LB. In fact, AD ϩ LB cases with Braak stages III or IV had similar APOE*4 allele frequencies to those with Braak stages V or VI (45 vs 48%).
Discussion. We confirm that there is a genetic association between the APOE*4 allele and LBs in AD.
Four prior studies reported an overrepresentation of APOE*4 alleles in cases with AD ϩ LB. 2, 6, 18 We also confirmed reports that men with APOE*4 have higher odds of having AD/LB than men without an APOE*4 allele. 6 However, the reasons accounting for these gender differences remain unclear.
Fifty-six percent of cases of neuropathologic AD in our sample had concomitant LB pathology. Other studies have reported a prevalence of DLB in sporadic AD cases that ranges from 7 to 30%. However, they did not use systematic AS immunohistochemistry for LB detection. [19] [20] [21] [22] [23] [24] [25] Two studies that also used the LB509 antibody reported that approximately 50% of cases with familial AD and Down syndrome with concomitant AD have coexistent LBs. 26, 27 Therefore, we anticipate that our observed LB prevalence is comparable with that observed in other AD research centers.
The presence of an APOE*4 allele may accelerate the underlying pathologic process of both AD and AD ϩ LB. Although there was no significant association between APOE*4 allele frequency and the extent of neocortical LBs, this association needs to be explored in larger autopsy samples.
The APOE*4 allele also appears to be associated with PD. Although previous studies have inconsistently reported this association, a recent large familybased association study showed that, independently of cognitive impairment, the APOE*4 allele is associated with both an increased risk of PD and a decreased age at onset of PD. 28 However, the mechanism by which an APOE*4 allele may influence the development of LBs in AD and PD remains unclear. AD and PD both involve the accumulation of insoluble protein deposits: ␤-amyloid and tau in AD and AS in PD. Recently, several studies have suggested that the pathologic cascades that lead to the accumulation of these different proteins may sometimes overlap or operate synergistically. 29 A study utilizing a doubly transgenic (tg) mouse model showed that mice expressing both human ␣-synuclein (hSYN) and human ␤-amyloid derived from amyloid precursor protein (hAPP) developed earlier motor deficits and more severe learning deficits than singly tg hAPP mice. 30 Doubly tg hSYN/hAPP mice also developed fibrillar intraneuronal inclusions of synuclein more similar to humans LBs than the amorphous accumulations of synuclein found in singly tg hSYN mice. Therefore, the development of one insoluble protein aggregate may precipitate the development of another protein aggregate. The presence of an APOE*4 allele may facilitate the development of these insoluble proteins.
On the other hand, APOE*4 may play a direct role in neurofibrillary tangle formation. 31 It is plausible that an APOE*4 allele influences the formation of intraneuronal protein aggregation. APOE*4 may stress the brain by causing synaptic disruption. 32 In response, the brain may attempt to restore neuronal integrity by increasing the production of tau or AS. Alternatively, the degradation process may decrease, resulting in protein accumulation and aggregation. Despite such hypotheses, the role of APOE*4 in the development of LBs remains unclear. Therefore, additional investigations focused on the pathogenesis of intraneuronal protein aggregation in AD and AD ϩ LB are necessary. 
Figure. Distribution of APOE*4 allele frequencies (%) by total Lewy body (LB) score classifications in cases with
Alzheimer disease ϩ LBs. The x axis indicates the number of subjects in the three total LB score categories (brainstem/amygdala predominant, limbic, and neocortical), and the y axis indicates APOE*4 allele frequencies.
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